The American Society of Hematology journal Blood Advances published an important "International Consensus Statement on the Management of Cardiovascular Risk of Bruton's Tyrosine Kinase Inhibitors in CLL" on 5 July 2022.
It provides "a management guideline for CV toxicities of BTKi developed by an international expert panel focusing on the treatment of patients with hematologic malignancies and risk of cardiovascular disease (CVD), with a focus on patients with CLL.'
The recommendations are the work of an international steering committee of 12 physicians including 'hematologists, oncologists, and cardio-oncologists with a specialist interest in CV toxicities to provide a diversity of clinical experience. The committee sought to make practical recommendations on the optimal selection of treatment for patients and effective ways to mitigate CV toxicities.' (my emphasis)
The statement provides an overview of current CLL treatments along with trial data regarding their CV toxicities.
The statement then provides some 'Practical recommendations for BTKi therapy' including advice in the following areas:
1 PRE-TREATMENT RECOMMENDATIONS including INITIAL WORKUP and SELECTING A COURSE OF TREATMENT
'Comprehensive patient history including:
Blood pressure measurement, Electrocardiogram, Concomitant medications, CV risk factor assessment: presence of diabetes, obesity, hypertension, dyslipidemia, chronic renal disease
History of valvular heart disease, History of arrhythmias, heart failure, or left ventricular dysfunction/reduced ejection fraction
History of ischemic heart disease
For patients with high CV risk or established CV disease: Echocardiogram, Baseline cardiac biomarkers, Consider using FRS-CVD65 score for stratification'
Patients with no CV risk factors: Any approved BTKi (If other safety concerns, favor more selective drugs (acalabrutinib or zanubrutinib) or Bcl-2 inhibitors)
Patients with CV risk (e.g. well-controlled AF, HTN): Consider 2nd-generation BTKis (acalabrutinib or zanubrutinib)'
2 RECOMMENDATIONS FOR PATIENTS WITH CV RISK
'Atrial fibrillation: Determine whether patient is high or low risk. Low risk cases may be safely treated with BTKis; Favor more 2nd-generation BTKis (acalabrutinib or zanubrutinib) or alternative treatments. BTKi treatment may be continued in consultation with MDT for patients with: Permanent/persistent AF, HTN, History of myocardial infarction. BTKis NOT recommended for patients with: History of ventricular arrhythmia, Family history of sudden cardiac death, Severe, uncontrolled HTN, Severe or uncontrolled congestive heart failure (LVEF<30%)
Hypertension: If HTN is well-controlled, BTKi therapy may be used; Monitor blood pressure at least bi-weekly for the first 3-6 months of BTKi therapy; Maintain early threshold for treatment during BTKi therapy
Congestive heart failure: Examine with echocardiogram; Restrict to <2 g daily sodium intake; Monitor weight daily; Monitor blood pressure twice weekly; Manage care with MDT (preferred) or in collaboration with a cardio-oncologist
Ventricular arrhythmias: Ibrutinib should be avoided; Risk of 2nd-generation BTKis (acalabrutinib or zanubrutinib) is not currently known
3 MANAGING CV TOXICITIES DURING TREATMENT
Emerging atrial fibrillation: Manage care using an MDT; If other risk factors are limited (e.g. CHA2DS2-VASc score = 0 or 1), BTKi therapy can be continued; Warfarin less preferred to alternative anticoagulant therapies; If recurrent events on ibrutinib, trial with acalabrutinib
Emerging HTN: Begin regular home blood pressure monitoring; New treatments for HTN or adjustments to ongoing treatments should be decided in conjunction with MDT; Follow management guidelines and avoid CYP3A4 ; inhibitors where possible; Non ACEi in the first instance; Use combination therapy if needed to attain systolic blood pressure control
Emerging CHF: Initiate ACEi/ARB/ARNI plus beta-blockers as tolerated and according to guidelines; Periodic echocardiogram or other EF assessment every 6-12 months in the setting of active CHF'
4 WHEN TO REFER TO CARDIO-ONCOLOGY
'Cardio-oncologists can be invaluable members of a patient’s MDT, however, there are still too few of these specialists to consult on all CLL patients with CV risk factors. It is therefore important to refer the most challenging cases, including patients with a history of ventricular tachycardia or arrhythmia or difficult to manage CHF, before beginning BTKi treatment. Providers should also consider referring patients with a history of substantial CV disease, including AF or CHF, difficult to control hypertension (more than 2 medications needed), or ongoing cardiac complications that require referral to a cardio-oncologist in cases of concern, but it is not necessary to do so routinely. In many cases, ongoing management by the patient’s own cardiologist is the most appropriate course of action. Additionally, a cardio-oncologist may be required to consult if there are any red flags in the initial workup, particularly AF on baseline.'
The statement concludes: 'BTKi therapy has changed the CLL treatment in substantial ways, but these drugs also present CV risks. New 2nd-generation BTKis have now been developed that are more selective for Band appear to have fewer off-target effects, providing the potential to reap the benefits of BTK inhibition while lessening the CV risks. The recommendations presented here take into account the available phase 3 data for BTKis in order to promote their safe and effective use. Optimizing heart failure, ventricular arrhythmia, and HTN control will likely improve tolerance and maintenance of BTKi therapy. However, additional studies are needed to identify the most optimal strategy across this growing class of drugs.'
More detail can be found in the full statement:
Farrukh T Awan, Daniel Addison, Feras Alfraih, Sergio J Baratta, Rodrigo Noronha Campos, MARIA SILVANA CUGLIARI, Yeow Tee Goh, Valery Alexandrovich Ionin, Stefanie Mundnich, Aaron L Sverdlov, Constantine S. Tam, Loïc Ysebaert; International Consensus Statement on the Management of Cardiovascular Risk of Bruton's Tyrosine Kinase Inhibitors in CLL. Blood Adv 2022; bloodadvances.2022007938. doi: doi.org/10.1182/bloodadvanc...
(After opening the link, select the PDF option for the full text version)
Abbreviations:
ACEi = angiotensin converting enzyme inhibitor
AF = Atrial Fibrillation
ARB = angiotensin receptor blocker
ARNI = angiotensin receptor-neprilysin inhibitor
CHF = Cardiac Heart Failure
CV = Cardiovascular; CVD = Cardiovascular Disease
FRS-CVD = Framingham risk score-cardiovascular disease
HTN = Hypertension
LVEF = left ventricular ejection fraction
MDT = multidisciplinary team
Note: This is an UNLOCKED post